Author: admin

  • Knowledge, attitudes, and prevention practices for hepatitis B and C virus infection among patients in the North Gondar zone, Northwest Ethiopia | Virology Journal

    Knowledge, attitudes, and prevention practices for hepatitis B and C virus infection among patients in the North Gondar zone, Northwest Ethiopia | Virology Journal

    Knowledge, attitudes, and practices play crucial roles in the prevention of hepatitis B and C viruses. Understanding the impact of KAP can help in designing effective public health interventions aimed at reducing the transmission of these viruses [18]. In the present study, 58 participants (15.1%) were male, whereas the majority (84.9%) was female. The ages of the participants ranged from 18 to 70 years, with an average age of 26.1 years (± 5.5). The predominance of female participants can largely be attributed to the inclusion of wards related to labor and delivery, immunization, and antenatal care, in which only female participants are visited. This demographic distribution also reflects a tendency toward younger individuals, particularly those in their 20s, as reproductive age typically begins at approximately 15 years.

    When we compared our findings on knowledge with those from other studies, we found similarities with a study conducted in Saudi Arabia, which reported that 50.5% of participants had good knowledge [19]. However, our results indicate a greater level of knowledge than similar studies in Cameroon, where only 22.1% demonstrated good knowledge; among sub-Saharan immigrants, 15%; in Ethiopia, 25%; in Pakistan, 23.6%; and in Malaysia, 38.8% exhibited good knowledge [13, 16, 20,21,22]. The observed differences in knowledge levels can indeed be attributed to variations in educational attainment among participants. In our study, the illiteracy rate was 26%, which is significantly lower than the rates reported in Cameroon (48.4%) and among sub-Saharan African immigrants (75.4%) [16, 21]. This disparity suggests that higher educational levels may contribute to better health knowledge [16, 21]. Furthermore, our analysis identified participants’ educational level and history of hospital admission as statistically significant factors associated with knowledge. This aligns with findings from studies conducted in Cameroon, Pakistan, and sub-Saharan Africa [13, 16, 21], which also indicate that education plays a crucial role in enhancing health knowledge [23]. A history of hospital admissions can enhance knowledge about hepatitis B and C through increased exposure to healthcare education, personal experiences, and ongoing medical care. Research also indicates that individuals with higher educational attainment tend to have a better understanding of the hepatitis B and C viruses [24].

    The attitudes of the participants indicated that fewer than half, specifically 180 (47%), with a 95% confidence interval of 41.8–52, had a positive attitude toward the hepatitis B and C viruses. This percentage is lower than the findings reported in Cameron (54.6%) and Gambia (70%). However, our results demonstrate a more favorable attitude than those of other studies conducted in Ghana, where only 33% of the respondents reported good attitudes, and in Pakistan, where 21.8% of the respondents reported good attitudes. This discrepancy can be attributed to the larger number of participants; 56.4% of the participants in Ghana [25] were illiterate, but in our study, 26% were illiterate. In this study, both participants’ level of education and residency were statistically associated with their attitudes. This finding aligns with other research conducted among sub-Saharan immigrants, as well as in Jordan and Ghana, where education has been shown to be statistically linked to attitudes [21, 25, 26]. In contrast, studies in Ethiopia, Pakistan, and Cameroon demonstrated that participants’ residency was a statistically significant factor associated with their attitudes [13, 16, 22]. The residency of individuals can shape their attitudes toward hepatitis B and C through factors such as access to healthcare, cultural influences, educational initiatives, and personal experiences. These elements collectively contribute to how communities perceive and respond to the challenges posed by these viral infections [16].

    In our study, the levels of prevention practices for HBV and HCV were categorized as follows: 173 participants (45.2%) demonstrated good practices, with a 95% confidence interval of 40–50.4, whereas 210 participants (54.8%) exhibited poor practices, with a 95% confidence interval of 49.6–60. Notably, these results indicate that the prevention practice levels among our participants were higher than those reported in similar studies, such as in Cameroon (24.3%), sub-Saharan immigrants (33.4%), Pakistan (33.1%), and Ethiopia, where 37.6% of participants had good prevention practices [13, 16, 21, 22]. This discrepancy may be attributed to differences in the educational levels of the participants. In our study, 26% of the participants were illiterate, whereas in Cameroon, 48.4% [16] of the participants had no education, and this figure rose to 75.4% among sub-Saharan immigrants [21]. Furthermore, in our research, the only variable that showed a statistically significant association with hepatitis B and C virus prevention practices was the participants’ attitudes toward these infections. This finding aligns with other studies conducted in Cameroon and among sub-Saharan immigrants, where participants’ attitudes were also statistically linked to their prevention practices [16, 21]. The attitudes of study participants toward hepatitis B and C viruses significantly affect their prevention practices, as supported by research conducted in Ethiopia and Pakistan [13, 22]. Positive attitudes can foster greater involvement in preventive measures, whereas negative perceptions may hinder effective prevention efforts [27].

    Continue Reading

  • Remy Cointreau sales rise, profit view lifted on China tariff deal – Reuters

    1. Remy Cointreau sales rise, profit view lifted on China tariff deal  Reuters
    2. Rémy Cointreau shares rise after Q1 beat, raised profit guidance  Investing.com
    3. Rémy Cointreau’s Strategic Turnaround Amid Tariff Challenges and Market Downturns  AInvest
    4. Remy Cointreau’s first-quarter sales rise 5.7%, beating forecast  104.1 WIKY
    5. Remy Cointreau lifts profit view as sales return to growth  MSN

    Continue Reading

  • Cambridge study finds positive and statistically-significant association between three types of air pollutant and dementia – Green Car Congress

    1. Cambridge study finds positive and statistically-significant association between three types of air pollutant and dementia  Green Car Congress
    2. Air pollution raises risk of dementia, say Cambridge scientists  The Guardian
    3. Increased air pollution exposure during midlife may harm brain health as we age  Medical Xpress
    4. Air pollution, car exhaust emissions may raise your risk of dementia: Study  Punjab News Express
    5. ‘The invisible threat’: Air pollution exposure over time raises the risk of dementia, study finds  Euronews.com

    Continue Reading

  • Energy use in the industry sector declines 5% in 2023 – News articles

    Energy use in the industry sector declines 5% in 2023 – News articles

    In 2023, the final energy consumption in the industry sector in the EU was 8 990 petajoules (PJ), down 5.3% compared with 2022 (9 489 PJ). The industry sector has had a long-term decline in energy use, falling almost a third since 1990. 

    Electricity and natural gas accounted for almost two-thirds of final energy consumption in the EU’s industry sector (32.6% and 31.3%, respectively). Oil and petroleum products accounted for 11.4 %, followed by renewables and biofuels (11.2%). Solid fossil fuels had a 6.0% share in the mix, derived heat 5.3%, whereas non-renewable waste accounted for 2.1%.

    Source dataset: nrg_bal_s

    Renewables biggest energy source in paper industry

    In one of the sub-sectors, the paper, pulp and printing industry, renewables and biofuels are by far the most important fuel group (302.5 PJ or 70.3%) for energy use.

    For the first time, renewables and biofuels (246.8 PJ or 33.9%) had the highest energy consumption share in the manufacturing of paper and other paper products (pulp excluded), ahead of electricity (236.9 PJ or 32.6%) and natural gas (147.3 PJ or 20.3%).

    Final energy consumption in the paper, pulp and printing industry by energy product in the EU, 2023. Bar chart - Click below to see full dataset.

    Source dataset: nrg_d_indq_n

    Continue Reading

  • Euro area economic and financial developments by institutional sector: first quarter of 2025

    Euro area economic and financial developments by institutional sector: first quarter of 2025

    25 July 2025

    • Euro area net saving decreased to €799 billion in four quarters to first quarter of 2025, compared with €813 billion one quarter earlier
    • Household debt-to-income ratio decreased to 81.7% in first quarter of 2025 from 83.8% one year earlier
    • Non-financial corporations’ debt-to-GDP ratio (consolidated measure) decreased to 67.2% in first quarter of 2025 from 68.4% one year earlier
    • Share of net wealth held by wealthiest 10% of households stood at 57.3% in 2024, largely unchanged from previous years.

    Total euro area economy

    Euro area net saving decreased to €799 billion (6.5% of euro area net disposable income) in the four quarters to the first quarter of 2025 compared with €813 billion in the four quarters to the previous quarter. Euro area net non-financial investment was broadly unchanged at €441 billion (3.6% of net disposable income), due to broadly unchanged net investment of all sectors (see Chart 1 and Table 1 in the Annex).

    Euro area net lending to the rest of the world decreased to €388 billion (from €401 billion previously) reflecting the decreased net saving and broadly unchanged net non-financial investment. Non-financial corporations’ net lending decreased to €130 billion (1.1% of net disposable income) from €156 billion, while that of households increased to €598 billion (4.9% of net disposable income) from €588 billion. Financial corporations’ net lending (€123 billion, 1.0% of net disposable income) and general government net borrowing were broadly unchanged, the latter contributing negatively to euro area net lending (-€463 billion, -3.8% of net disposable income).

    Chart 1

    Euro area saving, investment and net lending to the rest of the world

    (EUR billions, four-quarter sums)

    Sources: ECB and Eurostat.

    * Net saving minus net capital transfers to the rest of the world (equals change in net worth due to transactions).

    Data for euro area saving, investment and net lending to the rest of the world (Chart 1)

    Households

    Household financial investment increased at a broadly unchanged annual rate of 2.5% in the first quarter of 2025. Among its components, investment in currency and deposits grew at an unchanged rate of 3.0%. Investment in debt securities increased at a lower rate (3.0%, after 8.2%), while investment in shares and other equity grew at a higher rate (2.3%, after 1.8%) – the latter mainly due to investment fund shares.

    Households purchased, in net terms, mainly debt securities issued by the rest of the world, general government, and other financial institutions (see Table 1 below and Table 2.2. in the Annex). Households were overall net sellers of listed shares, selling predominantly listed shares of MFIs, while buying listed shares issued by the rest of the world (i.e. shares issued by non-euro area residents). Households increased their purchases of euro area non-money market investment fund shares, and continued to purchase money market fund shares, while purchases of investment fund shares issued by the rest of the world decelerated.

    The household debt-to-income ratio[1] decreased, to 81.7% in the first quarter of 2025 from 83.8% in the first quarter of 2024. The household debt-to-GDP ratio decreased, to 51.2% in the first quarter of 2025 from 52.3% in the first quarter of 2024 (see Chart 2).

    Table 1

    Financial investment and financing of households, main items

    (annual growth rates)

    Financial transactions

    2024 Q1

    2024 Q2

    2024 Q3

    2024 Q4

    2025 Q1

    Financial investment*

    2.0

    2.3

    2.4

    2.4

    2.5

    Currency and deposits

    1.5

    2.3

    2.5

    3.0

    3.0

    Debt securities

    41.4

    29.8

    17.1

    8.2

    3.0

    Shares and other equity**

    0.2

    0.4

    0.9

    1.8

    2.3

    Life insurance

    0.0

    0.4

    1.3

    1.6

    1.7

    Pension schemes

    2.0

    1.8

    1.9

    1.8

    2.1

    Financing***

    0.9

    1.2

    1.2

    1.6

    1.8

    Loans

    0.6

    0.6

    0.9

    1.3

    1.7

    Source: ECB.

    * Items not shown include: loans granted, prepayments of insurance premiums and reserves for outstanding claims and other accounts receivable.

    ** Includes investment fund shares.

    *** Items not shown include: financial derivatives’ net liabilities, pension schemes and other accounts payable.

    Data for financial investment and financing of households (Table 1)

    Chart 2

    Debt ratios of households and NFCs

    (percentages of GDP)

    Sources: ECB and Eurostat.

    * Outstanding amount of loans, debt securities, trade credits and pension scheme liabilities.
    ** Outstanding amount of loans and debt securities, excluding debt positions between NFCs
    *** Outstanding amount of loan liabilities.

    Data for debt ratios of households and non-financial corporations (Chart 2)

    Developments in household wealth distribution in 2024

    The Distributional Wealth Accounts show that household net wealth continued to increase in 2024, while wealth inequality, as measured by the Gini coefficient of net wealth, has remained broadly unchanged in recent years (see Chart 3). The share of household net wealth held by the wealthiest 10% of households stood at 57.3% at the end of 2024, largely unchanged from previous years.

    Chart 3

    Household net wealth distribution and wealth inequality

    (left-hand scale: EUR trillions; right-hand scale: percentages)

    Sources: ECB.

    The growth in net wealth across the various household wealth groups was primarily driven by valuation effects of both financial and non-financial assets, while contribution of net saving was stable but lower. Since the fourth quarter of 2019, net wealth has risen substantially across all wealth groups, with increases of 32% for the bottom 50% of the wealth distribution, 24% for the next 40%, and 26% for the top 10%. The developments varied between different asset classes, resulting in distinct portfolio dynamics across household wealth groups (see Chart 4). A significant portion of overall net wealth growth – more than half in each wealth group – was driven by increases in housing wealth. For the bottom 50% of households, deposits were the second-largest contributor (+9 percentage points), with smaller contributions from other wealth components. Among the next 40% of households, deposits also made a positive contribution (+4 percentage points) to net wealth growth, though this was largely offset by the negative effect of increasing mortgages (-3 percentage points). For the wealthiest 10% of households, the growth in net wealth was also supported by significant increases in business wealth (+6 percentage points) and investment fund shares (+3 percentage points).

    Chart 4

    Contributions to growth of household net wealth between Q1 2019 and Q4 2024

    (percentage points, percentage change)

    Sources: ECB.

    Note: The left-hand scale measures the percentage growth of net wealth and the percentage point contributions to net wealth growth of all other legend items.

    Non-financial corporations

    Financing of NFCs increased at a higher annual rate of 1.3% in the first quarter of 2025 (after 0.9% in the previous quarter). This was the result of an acceleration in financing by loans (2.0% after 1.3%) and trade credits (4.1% after 3.6%), while the financing via the issuance of debt securities and of equity grew at broadly unchanged rates (see Table 2).The acceleration in loan financing is mainly due to loans granted by MFIs (2.6% after 1.6%, see Table 3.2 in the Annex), by the rest of the world (1.6% after -0.2%), and by other financial institutions (-0.5% after -2.5%).

    NFCs’ debt-to-GDP ratio (consolidated measure) decreased to 67.2% in the first quarter of 2025, from 68.4% first quarter of 2024; the non-consolidated, wider debt measure decreased to 138.9% from 140.6% (see Chart 2).

    Table 2

    Financing and financial investment of NFCs, main items

    (annual growth rates)

    Financial transactions

    2024 Q1

    2024 Q2

    2024 Q3

    2024 Q4

    2025 Q1

    Financing*

    0.8

    0.9

    1.0

    0.9

    1.3

    Debt securities

    2.0

    2.9

    2.5

    1.5

    1.6

    Loans

    1.6

    1.4

    1.4

    1.3

    2.0

    Shares and other equity

    0.3

    0.6

    0.6

    0.4

    0.5

    Trade credits and advances

    1.0

    2.0

    2.5

    3.6

    4.1

    Financial investment**

    1.7

    1.8

    2.0

    1.8

    2.0

    Currency and deposits

    0.2

    2.6

    1.7

    2.4

    2.1

    Debt securities

    10.9

    8.1

    3.9

    2.1

    4.1

    Loans

    3.9

    3.7

    3.2

    2.6

    2.8

    Shares and other equity

    1.1

    0.9

    1.2

    0.7

    0.4

    Source: ECB.

    * Items not shown include: pension schemes, other accounts payable, financial derivatives’ net liabilities and deposits.

    ** Items not shown include: other accounts receivable and prepayments of insurance premiums and reserves for outstanding claims.

    Data for financial investment and financing of non-financial corporations (Table 2)

    For queries, please use the statistical information request form.

    Notes

    • These data come from a second release of quarterly euro area sector accounts for the first quarter of 2025 by the ECB and Eurostat, the statistical office of the European Union. This release incorporates revisions and completed data for all sectors compared with the first release on “Euro area households and non-financial corporations” of 3 July 2025.
    • The euro area and national financial accounts data of NFCs and households are available in an interactive dashboard.
    • The debt-to-GDP (or debt-to-income) ratios are calculated as the outstanding amount of debt in the reference quarter divided by the sum of GDP (or income) in the four quarters up to the reference quarter. The ratio of non-financial transactions (e.g. savings) as a percentage of income or GDP is calculated as the sum of the four quarters up to the reference quarter for both numerator and denominator.
    • The annual growth rate of non-financial transactions and of outstanding assets and liabilities (stocks) is calculated as the percentage change between the value for a given quarter and that value recorded four quarters earlier. The annual growth rates used for financial transactions refer to the total value of transactions during the year in relation to the outstanding stock a year before.
    • Hyperlinks in the main body of the statistical release lead to data that may change with subsequent releases as a result of revisions. Figures shown in annex tables are a snapshot of the data as at the time of the current release.
    • The release of results of experimental Distributional Wealth Accounts (DWA) for the first quarter of 2025 is planned for 29 August 2025 (tentative date).

    Continue Reading

  • Infinix HOT 60 Pro+ Officially Launches, Setting a New Global Record for the World's Slimmest 3D-Curved Screen Phone – PR Newswire

    1. Infinix HOT 60 Pro+ Officially Launches, Setting a New Global Record for the World’s Slimmest 3D-Curved Screen Phone  PR Newswire
    2. Here’s when the Infinix Hot 60 Pro+ will launch globally – GSMArena.com news  GSMArena.com
    3. Infinix unveils world’s slimmest curved screen phone in Kenya  Capitalfm.co.ke
    4. Infinix Hot 60 Pro+ unveiled as the world’s thinnest smartphone globally with 5,160 mAh battery  Notebookcheck

    Continue Reading

  • 201 million years ago, abundant atmospheric gas triggered a mass extinction: Study says history may repeat itself |

    201 million years ago, abundant atmospheric gas triggered a mass extinction: Study says history may repeat itself |

    Nature has rewritten the rules of survival more than once throughout the history of existence, witnessing asteroid impacts, super volcanoes, and the causes of mass extinction. There are many reasons for the complete disappearance of species, and one of these silent killers is ocean acidification, which is due to the buildup of carbon dioxide (CO₂) in the atmosphere, which then dissolves into seawater and disrupts marine chemistry.While many people associate today’s rising CO₂ levels and warming oceans with modern industrial activity, similar events have happened in Earth’s distant past, even long before humans ever walked the planet.Scientists now believe that carbon-driven ocean acidification was a major factor in some of Earth’s most significant mass extinction events, and surprisingly, the patterns from the past look similar to what we’re experiencing today.A study that was published in Nature Communications sheds light on one such ancient crisis

    Representative Image

    Acidification of the ocean can be harmful to the Earth’s future

    Roughly 201 million years ago, at the boundary between the Triassic and Jurassic periods, Earth’s oceans went through a major crisis. New research from the University of St Andrews and the University of Birmingham has confirmed that a sharp and prolonged drop in ocean pH, caused by a massive carbon dioxide surge, contributed directly to a global extinction event.

    What was the study all about?

    The study, led by scientists including Dr. James Rae and Dr. Sarah Greene, is the first to fully reconstruct ancient ocean pH levels using boron isotopes found in fossil oysters. These specimens were collected from Lavernock Point in Wales, which showed a significant drop in pH by at least 0.29 units, possibly more than 0.41. According to the researchers, this corresponds to a CO₂ level over 1300 parts per million (ppm). For comparison, current CO₂ levels are around 420 ppm.“The geological record tells us that major CO₂ release transforms the face of our planet, acidifying the ocean, and causing mass extinction,” said Dr. Rae in the university press release. “We have to act fast to avoid these outcomes in our future.”

    Representative Image

    The carbon release, estimated at over 10,000 gigatons, was likely driven by volcanic activity as the supercontinent Pangaea began to break apart. The resulting acidification devastated coral reefs and shell-forming marine life, creating a “reef gap” that lasted hundreds of thousands of years.Dr. Greene said, “This warning from the past should give us fresh cause to step up efforts to reduce human greenhouse gas emissions.”Today’s acidification is happening even faster, making this ancient event a chilling parallel and a reminder that Earth doesn’t need an asteroid to spark a mass extinction. Sometimes, it can only be rising carbon levels due to pollution.


    Continue Reading

  • Get Microsoft Office 2021 for Mac for just $69.97

    Get Microsoft Office 2021 for Mac for just $69.97

    TL;DR: Save 68% on Microsoft Office 2021 for Mac while codes last. Here’s everything that’s included:


    Get Microsoft Office 2021 for Mac for life for just $69.97.

    What you get with Microsoft Office Home & Business for Mac 2021:

    • Word: Create clean, professional documents for work, school, or anything in between.

    • Excel: Handle spreadsheets, analyze data, and build budgets with ease.

    • PowerPoint: Design presentations that actually keep people’s attention.

    • Outlook: Manage your email, calendar, and contacts all in one place.

    • Teams: Stay connected and collaborate with your team or classmates.

    • OneNote: Jot down ideas, organize notes, and keep your brain clutter in check.

    Unlike Microsoft 365, this is the lifetime version of Microsoft Office with no subscriptions or recurring fees. You’ll get an instant download link and software activation key via email right after purchase, so you can start using Office right away.

    Download Microsoft Office for Mac while it’s on sale for $69.97 (reg. $219). No coupon is needed.

    Mashable Deals

    StackSocial prices subject to change.

    Continue Reading

  • How do the microplastics in our bodies affect our health?

    How do the microplastics in our bodies affect our health?

    “We know that microplastics are everywhere, even in the indoor environment. If they’re in your air, you’re still taking in microplastics at low levels when you’re asleep,” says Couceiro. “So we would like, if it’s possible, to speak to manufacturers about how to avoid them, whether they can stop making certain plastics in the first place. For example, for people who go into hospital to be treated for respiratory diseases, the masks are plastic, and the tubing is plastic. So can we find better alternatives which prevent them getting into the system in the first place?”

    Continue Reading

  • FDA considers removing warning labels on hormone replacement therapies : Shots

    FDA considers removing warning labels on hormone replacement therapies : Shots

    Treatments and best practices on when to prescribe hormone therapy and what medications to use have evolved in recent years.

    MStudioImages/E+/Getty Images


    hide caption

    toggle caption

    MStudioImages/E+/Getty Images

    When obstetrician JoAnn Pinkerton spoke on a Food and Drug Administration panel recently, she didn’t mince words.

    “Please stop harming women,” she said.

    Pinkerton argues that the FDA’s black box warning labels on hormone replacement therapies make women reluctant to take medications that can be beneficial for treating the symptoms of menopause.

    Pinkerton was one of twelve doctors — many of them experts in obstetrics and women’s health — who asked the FDA to remove the warning labels for vaginal low-dose estrogen treatment.

    The medication is typically prescribed to women in order to mitigate symptoms of menopause or perimenopause. Unlike other systemic hormone therapy treatments which are absorbed by the whole body, it is delivered locally — through a patch, a cream or a ring.

    The black box warning is the strongest safety label the FDA can put on a prescription medication. And Pinkerton and others argue that such a warning for low-dose estrogen treatment is unnecessary.

    The medication is often prescribed to prevent or address symptoms associated with menopause including frequent urinary tract infections, vaginal dryness, and pain during sexual intercourse.

    “ The boxed warning is not supported by science,” says Pinkerton. “It overstates risk.”

    Pinkerton described a recent patient suffering from such symptoms, for whom she had written a prescription. She pulls out the tube, “and it says warning: Endometrial cancer, cardiovascular disorders, probable dementia and breast cancer. And she looks at it, her partner or spouse looks at it and they throw it in the trash,” Pinkerton recounts.

    A pendulum swing toward HRT

    The consensus from the medical establishment on the safety of hormone treatment for menopause has changed dramatically in recent decades. In 2002, researchers partly halted a large study on women’s health — the Women’s Health Initiative — out of concern that hormone therapy was associated with increased risk of cancer and stroke. Breast cancer was a particular concern. Since then, researchers and doctors have determined the cancer risk was overstated.

    Treatments and best practices around when to prescribe hormone therapy and what medications exactly to prescribe have evolved in recent decades.

    Many doctors in women’s health have advocated for this change for years without success.  Recent studies suggest the cancer risks of some hormone therapies are quite low and there are significant benefits for women going through menopause. This is a pet issue for Dr. Marty Makary — the current FDA commissioner. Makary is a surgeon, not an obstetrician. He convened the panel.

    “Fifty million plus women have not been offered the incredible potential health benefits of hormone replacement therapy,” Makary said in opening remarks at the panel, “because of medical dogma.”

    Makary said his own family could have benefited from this treatment when it fell out of favor with the medical establishment.

    “ One of those women was my mother,” he said, “who went through perimenopause around that time.”

    Obstetricians and gynecologists interviewed for this story agreed they would like to see the black box label removed for low-dose vaginal estrogen treatments that carry lower cancer risk.

    “ I usually will make a little joke about, hey, we’ve been working for many years to try to get that black box warning removed, but you know, how slow government things can take,” said Dr. Monica Christmas, who regularly prescribes such treatments to her patients. Christmas is an OBG-GYN who is also the associate medical director for The Menopause Society.

    Christmas expressed reticence, however, about removing labels for systemic estrogen, which carries a different risk profile for cancer.

    “ For the vast majority of people, the risk is low, even for systemic hormone therapy,” said Christmas, “but it’s not zero.”

    Christmas said the black box warning can prompt doctors and patients to have necessary conversations about the risks and benefits of such medications.

    The FDA panel focused primarily on low-dose estrogen, but Makary also hinted at removing the label for systemic therapy, mentioning the benefits as suggested in some studies for reduced risk of osteoporosis, among others.

    “We want to learn from all of you,” Makary said to the panel members, “help guide us as we think through what should be done here at the FDA.”

    “This was theater, not scientific evaluation.”

    The panel was a departure from typical decision making at the FDA.

    “This was theater, this was not scientific evaluation,” said Adriane Fugh-Berman a professor of Pharmacology at Georgetown University. Fugh-Berman is skeptical of removing such labels and points out that the FDA usually has a more rigorous process to inform these kinds of changes.

    “That process is being undermined and distorted,” she said.

    (Fugh-Berman has worked as a paid expert witness in litigation against pharmaceutical companies accused of overselling the benefits of hormone therapy and contributing to breast cancer.)

    FDA decision making often involves a period of public input. Committees are appointed to study issues and make recommendations. Fugh-Berman said she would have preferred to see a period of public comment as well as an expert committee that included a wider range of experts such as epidemiologists, oncologists, and experts in public health.

    Representatives from the FDA did not respond to a request for comment on this story, or offer comment on future steps in a potential process to remove the warnings from prescriptions.

    At least one obstetrician celebrated the increased attention to this issue, even if it came through an unconventional process.

    “I was very happy,” said Rachel Rubin, a urologist with a specialty in sexual medicine. Rubin was also a panel member. “ The fact that the head of the FDA wants to be talking about this topic is extraordinary and something we’ve all been dreaming about,” she says.

     Rubin acknowledged the departure from the level of rigor to which the FDA usually adheres.

    “Were there voices missing? Of course,” she says. But given this opportunity, she said, it’s worth showing up to, “fight for something you’ve been fighting for for decades.”

    OB-GYN Monica Christmas wouldn’t say whether she thought the composition of the panel should have been different or the process more rigorous. But she did express concern that enthusiasm for hormonal treatment for menopause may be eclipsing the necessary risk-benefit analysis that patients and doctors need to make when considering these medications.

    “Hormone therapy has become synonymous with menopause,” she says. And she cautions that women should rule out other issues before they jump to hormone therapy.

    “It’s almost like, ‘Oh, I’m in menopause,’ says Christmas, “I should have to be on hormone therapy for all of these magical or mystical benefits.”

    Continue Reading